TransMedics Group, Inc.
TMDX Healthcare Medical Devices
TransMedics Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $605.5 million, up 37.1% from fiscal 2024.
- Revenue
- +41.2%
- EPS
- −31.0%
- Free cash flow
- −55.4%
- Total debt
- −89.3%
Quarter to September 2026, against a year earlier
Follow TMDX
Alert me
TransMedics Group, Inc. (TMDX) P/S ratio
As of 5 November 2026, TransMedics Group, Inc. (TMDX) trades at a P/S ratio of 3.3×. Over the past ten years it has ranged from 2.1× (May 2019) to 46.1× (March 2021); the current reading is higher than 2% of that period. That is above the Medical Devices industry median of 2.5× and below the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 6.8× | 45.55% |
| FY2024 | 4.7× | (54.60%) |
| FY2023 | 10.3× | (42.77%) |
| FY2022 | 18.1× | 3.29% |
| FY2021 | 17.5× | (8.80%) |
| FY2020 | 19.2× | 67.60% |
| FY2019 | 11.4× | 447.51% |
| FY2018 | 2.1× | 0.00% |
| FY2017 | 2.1× | 0.00% |
| FY2016 | 2.1× | — |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 4.0× | 15.79% |
| Jun 2026 | 3.4× | (36.08%) |
| Mar 2026 | 5.4× | (21.29%) |
| Dec 2025 | 6.8× | 1.06% |
| 31 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| NVCR NovoCure Limited compare | 2.2× |
| INSP Inspire Medical Systems, Inc. compare | 2.2× |
| NEOG Neogen Corporation compare | 2.9× |
| TMDX TransMedics Group, Inc. | 3.3× |
| UFPT UFP Technologies, Inc. compare | 3.6× |
| ESTA Establishment Labs Holdings Inc. compare | 7.9× |
| AXGN AxoGen, Inc. compare | 10.1× |
| BFLY Butterfly Network, Inc. compare | 13.1× |
| ALMR Alamar Biosciences, Inc. compare | 17.8× |
| Medical Devices industry median | 2.5× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on TMDX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement